登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603309 证券简称：维力医疗 公告编号：2026-001 广州维力医疗器械股份有限公司 关于控股股东部分股份解除质押的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 近日，高博投资将上述质押给澳门国际银行股份有限公司的2,000万股无限售流通股进行了提前赎回， 相关股份解除质押手续已于2025年12月30日通过中国证券登记结算有限责任公司办理完毕。股份被解质 情况如下： ■ 截至目前，本次解质的股份无后续质押计划。如高博投资未来进行股份质押，公司将根据相关法律法规 要求及时履行信息披露义务。 特此公告。 重要内容提示: ● 截至2025年12月31日，公司控股股东高博投资（香港）有限公司合计持有公司股份9,201.92万股，占 公司总股本的31.53%，累计质押公司股份2,600万股，占其所持公司股份的28.25%，占公司总股本的 8.91%。 广州维力医疗器械股份有限公司（以下简称"公司"）于2025年12月31日收到公司控股股东高博投资（香 港） ...

Group 1 - The company expects a net profit increase of over 50% for the fiscal year 2025, with the performance period from January 1, 2025, to December 31, 2025 [1] - The company reported a production of approximately 4.9 million tons of potassium chloride and 46,500 tons of lithium carbonate, with sales figures of about 3.81 million tons and 45,600 tons respectively [2] - The price of potassium chloride has risen compared to the previous year, while lithium carbonate prices have shown volatility but are recovering in the second half of the year, contributing to the overall growth in performance [2] Group 2 - The company has successfully passed the re-examination for high-tech enterprise qualification, which will allow it to recognize deferred tax assets, further boosting net profit [2] - The financial data in the performance forecast has not been audited by a registered accounting firm, and the company has communicated with the accounting firm regarding significant matters without major disagreements [1][2]

北京商报讯（记者 郭秀娟 王悦彤） 1月4日，煌上煌公告称，公司近日收到江西省相关部门联合下发的 《高新技术企业证书》，编号为GR202536000751，发证时间为2025年10月29日，有效期三年。根据规 定，公司在2025—2027年可按15%的税率缴纳企业所得税，此次认定不会对当期经营业绩产生重大影 响。 ...

Core Viewpoint - The company, Huangshanghuang (002695.SZ), has received the "High-tech Enterprise Certificate" from the Jiangxi Provincial Department of Science and Technology, Jiangxi Provincial Department of Finance, and the State Taxation Administration Jiangxi Provincial Taxation Bureau, allowing it to benefit from preferential tax policies for high-tech enterprises [1] Group 1 - The company will enjoy a reduced corporate income tax rate of 15% for three years (2025-2027) following its recognition as a high-tech enterprise [1] - The recognition as a high-tech enterprise is based on the "High-tech Enterprise Recognition Management Measures" and the "Corporate Income Tax Law of the People's Republic of China" [1] - This recognition is not expected to have a significant impact on the company's current operating performance [1]

Core Viewpoint - The company, Huangshanghuang (002695.SZ), has received the "High-tech Enterprise Certificate" from the Jiangxi Provincial Department of Science and Technology, Jiangxi Provincial Department of Finance, and the State Taxation Administration Jiangxi Provincial Taxation Bureau, allowing it to benefit from preferential tax policies for high-tech enterprises for three years from 2025 to 2027 [1] Summary by Categories Company Recognition - The company has been recognized as a high-tech enterprise, which is a significant achievement that may enhance its reputation and market position [1] Tax Benefits - As a result of this recognition, the company will enjoy a reduced corporate income tax rate of 15% for three years, in accordance with relevant regulations [1] Impact on Financial Performance - The recognition as a high-tech enterprise is not expected to have a significant impact on the company's current operating performance [1]

Core Viewpoint - The company has received a "High-tech Enterprise Certificate" from relevant departments in Jiangxi Province, which allows it to benefit from a reduced corporate income tax rate of 15% for the years 2025 to 2027 [1] Group 1 - The certificate number is GR202536000751, issued on October 29, 2025, and is valid for three years [1] - The recognition as a high-tech enterprise is not expected to have a significant impact on the company's current operating performance [1]

Core Viewpoint - Salt Lake Co. is expected to achieve significant growth in net profit for the year 2025, with a potential increase of up to 90.65% year-on-year, driven by stable business performance and favorable pricing trends in key products [2][3] Group 1: Financial Performance - The projected net profit attributable to shareholders for 2025 is estimated to be between 829 million and 889 million yuan, compared to 466.31 million yuan in the previous year, reflecting a year-on-year growth of 77.78% to 90.65% [2] - The net profit after deducting non-recurring gains and losses is expected to be between 823 million and 883 million yuan, up from 440.05 million yuan last year, indicating a growth of 87.02% to 100.66% [2] - The basic earnings per share are projected to be between 1.56 yuan and 1.69 yuan, compared to 0.8812 yuan per share in the previous year [2] Group 2: Growth Drivers - The company's main business has shown steady development, with an estimated production of approximately 4.9 million tons of potassium chloride and sales of about 3.81 million tons in 2025 [3] - The production of lithium carbonate is expected to be around 46,500 tons, with sales of approximately 45,600 tons [3] - The prices of potassium chloride products have increased compared to the previous year, while lithium carbonate prices have shown volatility but are gradually recovering in the second half of the year, contributing to the overall growth in performance [3] - The successful re-examination of high-tech enterprise qualifications has allowed the company to recognize deferred tax assets based on accounting standards, further enhancing net profit [3]

Summary of Key Points Core Viewpoint - Vili Medical (603309) has experienced a slight decline in stock price, with a current market capitalization of 3.967 billion yuan, ranking 87th in the medical device sector and 3948th in the A-share market [1]. Company Announcements - Vili Medical announced a cash dividend of 0.2 yuan per share (before tax) for Q3 2025, with the record date set for January 7, 2026, and the payment date on January 8, 2026. The total cash dividend distribution amounts to approximately 58.37 million yuan based on a total share count of 291,871,418 shares [1][3]. - The wholly-owned subsidiary, Jiangxi Langhe Medical Device Co., Ltd., has received re-certification as a high-tech enterprise, valid for three years from October 29, 2025. This allows the subsidiary to continue benefiting from a 15% corporate income tax rate from 2025 to 2027 [2][3]. - The controlling shareholder, Gaobo Investment (Hong Kong) Co., Ltd., has released a pledge on 20 million shares, which represents 6.85% of the total share capital. As of December 31, 2025, Gaobo Investment holds 31.53% of the company's shares, with a total of 26 million shares pledged [2][3].

Core Viewpoint - Antu Biology (603658.SH) has received the "High-tech Enterprise Certificate" for its wholly-owned subsidiary Zhengzhou Yimeno Biotechnology Co., Ltd. and its secondary subsidiary Zhengzhou Biaoyuan Biotechnology Co., Ltd. This recognition allows the subsidiaries to benefit from tax incentives for three years from 2025 to 2027 [1] Group 1 - The subsidiaries were re-certified as high-tech enterprises after the expiration of their previous certificates [1] - The certificate numbers are GR202541002114 and GR202541001628, with an issuance date of November 4, 2025, and a validity period of three years [1] - The subsidiaries will enjoy a corporate income tax rate of 15% as part of the national tax incentives for high-tech enterprises [1]

Group 1 - Company Antu Biology (603658.SH) announced that its wholly-owned subsidiary Zhengzhou Yimeinuo Biotechnology Co., Ltd. and its secondary subsidiary Zhengzhou Biaoyuan Biotechnology Co., Ltd. have recently received the "High-tech Enterprise Certificate" from the Henan Provincial Department of Science and Technology, Henan Provincial Department of Finance, and the State Taxation Administration of Henan Province [1] - The certificate numbers are GR202541002114 and GR202541001628, with both issued on November 4, 2025, and valid for three years [1] - This recognition is a renewal of the previous high-tech enterprise certification, allowing the subsidiaries to continue enjoying tax benefits under the national policy for high-tech enterprises, specifically a corporate income tax rate of 15% from 2025 to 2027 [1]